Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Aptorum Group Ltd Class A (APM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: APM (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $80
1 Year Target Price $80
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -88.05% | Avg. Invested days 19 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 15.82M USD | Price to earnings Ratio - | 1Y Target Price 80 |
Price to earnings Ratio - | 1Y Target Price 80 | ||
Volume (30-day avg) 2 | Beta -0.28 | 52 Weeks Range 0.46 - 4.47 | Updated Date 08/28/2025 |
52 Weeks Range 0.46 - 4.47 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.78 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -8.33% | Return on Equity (TTM) -30.62% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 18304089 | Price to Sales(TTM) 23.35 |
Enterprise Value 18304089 | Price to Sales(TTM) 23.35 | ||
Enterprise Value to Revenue 31.22 | Enterprise Value to EBITDA -0.45 | Shares Outstanding 5346820 | Shares Floating 3404715 |
Shares Outstanding 5346820 | Shares Floating 3404715 | ||
Percent Insiders 19.48 | Percent Institutions 0.72 |
Upturn AI SWOT
Aptorum Group Ltd Class A
Company Overview
History and Background
Aptorum Group Limited (APM) is a pharmaceutical company dedicated to developing and commercializing novel therapeutics to tackle unmet medical needs. Founded in 2016, it has focused on research and development across various disease areas, with a recent strategic pivot.
Core Business Areas
- Pharmaceuticals: Focuses on developing and commercializing therapeutic candidates for infectious diseases, autoimmune disorders, and other unmet medical needs.
- Drug Discovery: Engages in early-stage drug discovery activities, including identifying and validating potential drug targets.
- Diagnostics: Developing rapid diagnostic solutions for infectious diseases and other medical conditions.
Leadership and Structure
The leadership team includes Ian Huen, CEO, and other key executives in research and development, and finance. The organizational structure comprises research, development, and commercialization divisions.
Top Products and Market Share
Key Offerings
- ALS-4 (SACT-1): A preclinical-stage compound targeting Staphylococcus aureus infections. Market share is currently 0 due to being preclinical, but would compete with existing antibiotic treatments. Competitors: Merck (MRK), Pfizer (PFE), Roche (RHHBY).
- Small molecule drug candidates: Preclinical-stage small molecule drug candidates targeting autoimmune diseases. Market share is currently 0 due to being preclinical. Competitors: AbbVie (ABBV), Johnson & Johnson (JNJ).
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by intense competition, high R&D costs, stringent regulatory requirements, and increasing pricing pressures. Innovation and strategic partnerships are crucial for success.
Positioning
Aptorum Group is a relatively small player in the pharmaceutical industry, focusing on niche therapeutic areas. Competitive advantages could come from successful development and commercialization of its pipeline assets.
Total Addressable Market (TAM)
The global pharmaceutical market is valued at over $1.4 trillion and continues to grow. Aptorum's success hinges on capturing specific market segments with its pipeline products.
Upturn SWOT Analysis
Strengths
- Diverse pipeline of preclinical assets
- Experienced management team
- Focus on unmet medical needs
Weaknesses
- Limited financial resources
- High dependence on successful clinical trials
- Lack of established commercial infrastructure
Opportunities
- Strategic partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- FDA fast track designation for promising drug candidates
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Intellectual property challenges
Competitors and Market Share
Key Competitors
- JNJ
- PFE
- MRK
- ABBV
- BMY
Competitive Landscape
Aptorum faces intense competition from established pharmaceutical companies with greater financial resources and established commercial infrastructure. Its success depends on its ability to innovate and forge strategic partnerships.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by fundraising and advancements in its pipeline.
Future Projections: Future growth depends on successful clinical trials and regulatory approvals of its drug candidates. Analyst estimates vary widely due to the inherent uncertainty in the pharmaceutical industry.
Recent Initiatives: Recent strategic initiatives include focusing on infectious diseases and autoimmune disorders, and progressing preclinical assets towards clinical trials.
Summary
Aptorum Group is a small pharmaceutical company with a promising but early-stage pipeline. It faces significant challenges in terms of funding, regulatory approvals, and competition. Successful clinical trials and strategic partnerships are crucial for its long-term viability, and while the company focuses on unmet needs that allows them to explore market gaps, they are competing against pharmaceutical giants and need to be able to obtain more market share by creating stronger products than what's already available.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is based on available information and subject to change. Investment decisions should be based on individual due diligence and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aptorum Group Ltd Class A
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2018-12-18 | Founder, CEO & Executive Director Mr. Chung Yuen Huen | ||
Sector Healthcare | Industry Biotechnology | Full time employees 1 | Website https://www.aptorumgroup.com |
Full time employees 1 | Website https://www.aptorumgroup.com | ||
Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa; and RPIDD, a liquid biopsy rapid pathogen diagnostic which is in preclinical trial to treat pathogen molecular diagnostics. The company also develops SACT-COV19, a repurposed small molecule which is in preclinical trial for the treatment of coronavirus disease; SACT-2 and SACT-3; ALS-1, a small molecule which is in preclinical trial to treat bacterial infections caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus (MRSA); and ALS-2/3, a small molecule which is in preclinical trial for the treatment of gram+ve bacterial infections. In addition, it is developing NLS-1, which is in preclinical trial for the treatment of endometriosis; DLS-1+2, which is in preclinical trial to treat NSCLC with mutation; DLS-3, which is in preclinical trial to treat autoimmune disease; CLS-1, a macromolecule, which is in preclinical trial to treat obesity; and CLS-1 and CLS-3. Further, the company offers NativusWell DOI (NLS-2), a dietary supplement for women undergoing menopause; and provides management services. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.